• Title/Summary/Keyword: combination chemotherapy

Search Result 457, Processing Time 0.047 seconds

An 87-year-old patient with repeated oligorecurrences over six years whose disease were treated with radiotherapy alone

  • Yun, Hyong Geun
    • Radiation Oncology Journal
    • /
    • v.32 no.4
    • /
    • pp.266-271
    • /
    • 2014
  • In the clinical state of oligometastases or oligorecurrence, a transitional state between localized and widespread systemic disease, local control of the disease may yield improved systemic control. Radiotherapy may be a good means for controlling oligometastatic tumors, particularly in very old patients for whom surgery may be infeasible. A combination of systemic therapy and local therapy is necessary to prevent systemic progression. Some kinds of cancers found in the elderly are known to be somewhat indolent for systemic progression. So, for very old patients who refuse or cannot tolerate chemotherapy, the use of radical radiotherapy alone to treat oligorecurrences may be very helpful. We successfully treated an 87-year-old patient who had been diagnosed with oligorecurrences three times over six years with radiotherapy alone. The patient is now, about four years after his first radiotherapy for liver metastasis, alive without any evidence of cancer and with fully active performance status.

Spontaneous Regression of Pineal Germinoma - Case Report - (자연 소실된 송과체 배아종 - 증례보고 -)

  • Cheong, Jin Hwan;Kim, Jae Min;Bak, Koang Hum;Kim, Choong Hyun;Oh, Suck Jun
    • Journal of Korean Neurosurgical Society
    • /
    • v.30 no.10
    • /
    • pp.1224-1228
    • /
    • 2001
  • Germinoma is a rare central nervous system neoplasm in children and young adults. It is well known that a malignant primary neoplasm can be cured by conventional radiation therapy alone or reduced-volume and field irradiation in combination with chemotherapy. The authors report a very rare case of a pineal germinoma, which was completely disappeared after repeated diagnostic brain computed tomography(CT) with review of pertinent literature. There has been neither tumor recurrence nor metastasis during follow-up period.

  • PDF

EFFICACY OF FEED ADDITIVE SULFAMONOMETHOXINE AND ORMETOPRIM AGAINST CHICKEN INFECTIOUS CORYZA : A CASE STUDY

  • Nakai, Y.;Ogimoto, K.;Kuwano, A.;Nakamura, K.;Kato, M.
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.4 no.1
    • /
    • pp.21-24
    • /
    • 1991
  • A mixed infection of Haemophilus paragallinarum (Hpg), Mycoplasma gallisepticum (MG) and M. synoviae (Ms) was detected in layers of a poultry farm in Iwate prefecture in Japan by pathological, serological and bacteriological investigation. Hpg strains were isolated from three of five birds investigated and all strains were identified to be type C. The Hpg isolates were more susceptible in vitro to a combination of sulfamonomethoxine and ormetoprim (Ektecin) than each of sulfamethoxasol, sulfamonomethoxine, oxytetracycline, tetracycline, streptomycin, erythromycin and thianphinicol. After a total of six days' medication of 1% feed additive Ektecin, symptoms of infectious coryza of hens in the farm almost disappeared and no Hpg was detected even from birds showing nasal discharge.

Development of the 3rd Generation Anticancer Platinum Complex as New Drug

  • Cho, Yong-Baik;Ph. D.
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2002.07a
    • /
    • pp.97-102
    • /
    • 2002
  • Life Science Research Center of SK Chemicals has developed a 3rd-generation anticancer platinum drug for the first time in the nation′s 100-year-old pharmaceutical industry. The Korea Food and Drug Administration (KFDA) approved the sale of "Sunpla" (code name SKI 2053R, general name : Heptaplatin) on July 14, 1999 for the treatment of advance, metastatic gastric cancer. Cisplatin, the 1 st-generation anticancer drug, which was developed by Bristol-Myers of the United States in 1976, is one of the most potent anticancer drugs and is a major component of combination chemotherapy for a variety of human cancers. However its clinical usefulness has frequently been limited not only by undesirable side effects such as severe renal toxicity, nausea, vomiting, ototoxicity, and neurotoxicity but also by the development of resistance. Carboplatin, the 2nd-generation anticancer platinum drug, which was also developed by Bristol-Myers in 1986, has modified the problems of the renal and gastrointestinal toxicities of cisplatin. Carboplatin, however, has no enhanced therapeutic efficacy over cisplatin and does not possess the property to overcome cross-resistance to cisplatin.

  • PDF

Primary endodermal sinus tumor of the mediastium -A case report- (종격동에 발생한 원발성 내배엽동종 -수술치험 1예 보고-)

  • 최영호
    • Journal of Chest Surgery
    • /
    • v.19 no.3
    • /
    • pp.494-499
    • /
    • 1986
  • Malignant germ cell tumors which have the same morphological appearance as germinal tumor of the gonad are sometimes found in the anterior mediastinum. Pure endodermal sinus tumor among them is very rare. It is highly malignant and usually extensively invasive at the time of surgical consideration. The prognosis is poor, but improvements in systemic chemotherapy regimens may improved the outlook. A case of primary endodermal sinus tumor of the mediastinum was presented. He was a 23-year-old male with anterior chest pain, tenderness and exertional dyspnea for 1 month. The tumor was well encapsulated and adhered to pericardium. The microscopic appearance was indistinguishable from that of the analogous gonadal neoplasm. The patient has treated with combination of surgery and radiotherapy as daily 180 rad for 6 weeks schedule, and then has follow up about 3 months with early recurrence.

  • PDF

Metachronous Liver Metastasis Resulting from Early Gastric Carcinoma after Subtotal Gastrectomy Following Endoscopic Resection: A Case Report

  • Oh, Sung Jin;Suh, Byoung Jo
    • Journal of Gastric Cancer
    • /
    • v.15 no.2
    • /
    • pp.139-142
    • /
    • 2015
  • Hepatic metastasis of early gastric cancer (EGC) following subtotal gastrectomy with lymphadenectomy is rare. We report the case of a 61-year-old male patient who was diagnosed with EGC that was initially treated using endoscopic submucosal dissection (ESD) and subsequently underwent laparoscopic subtotal gastrectomy. Histopathological examination of the patient's ESD specimen showed a moderately differentiated tubular adenocarcinoma invading the submucosa without lymphatic invasion. The deep margin of the specimen was positive for adenocarcinoma, and he subsequently underwent laparoscopic distal gastrectomy. The patient developed liver metastasis 15 months after the operation and then underwent liver resection. Histology of the resected specimen confirmed the diagnosis of two foci of metastatic adenocarcinoma originating from stomach cancer. Immunohistochemical analysis of the specimen demonstrated overexpression of human epidermal growth factor receptor 2. The patient was treated with trastuzumab in combination with chemotherapy consisting of capecitabine and cisplatin. Twenty-four months after the operation, the patient remained free of recurrence.

Tankyrase: Function and Tankyrase Inhibitor in Cancer

  • Kim, Mi Kyung
    • Biomedical Science Letters
    • /
    • v.24 no.3
    • /
    • pp.150-156
    • /
    • 2018
  • Tankyrases are multifunctional poly (ADP-ribose) polymerases that regulate a variety of cellular processes including WNT signaling, telomere maintenance, regulation of mitosis, and many others. Tankyrases interact with target proteins and regulate their interactions and stability through poly (ADP-ribosyl) ation. In addition to their roles in telomere maintenance and regulation of mitosis, tankyrase proteins regulate tumor suppressors such as AXIN, PTEN, and AMOT. Therefore, tankyrases can be effective targets for cancer treatment. Tankyrase inhibitors could affect a variety of pathways that are carcinogenic (essential for the unlimited proliferation of human cancer cells), including WNT, AKT, YAP, telomere maintenance, and regulation of mitosis. Recently, new aspects of the function and mechanism of tankyrases have been reported and several tankyrase inhibitors have been identified. Also, it has been proposed that the combination of conventional chemotherapy agents with tankyrase inhibitors may have synergistic anti-cancer effects. Based on this, it is expected that more advanced and improved tankyrase inhibitors will be developed, enabling new therapeutic strategies against cancer and other tankyrase linked diseases. This review discusses tankyrase function and the role of tankyrase inhibitors in the treatment of cancer.

Long-term Chemotherapy with Hydroxyurea in a Dog with Suspected Intracranial Meningioma

  • Jung, Dong-In;Lim, Chae-Young;Kang, Byeong-Teck;Kim, Ju-Won;Yoo, Jong-Hyun;Park, Hee-Myung
    • Journal of Veterinary Clinics
    • /
    • v.25 no.6
    • /
    • pp.514-517
    • /
    • 2008
  • A 9-year-old female mixed breed dog was presented due to cluster seizure episode. A mass in the frontal lobe was noted on brain magnetic resonance imaging (MRI). The dural tail sign was identified on contrast MR images. Based on MRI findings, intracranial meningioma was suspected strongly. The patient's symptom was controlled well by a combination therapy of hydroxyurea and prednisolone, and survived for fourteen months after diagnosis. This case report demonstrated that the clinical findings, imaging characteristics of a dog with suspected intracranial meningioma and long-term survival after hydroxyurea plus prednisolone therapy.

Multimodal Treatment of Poorly Differentiated Tracheobronchial Carcinoma in a Persian Cat

  • Park, Yohan;Song, Kunho
    • Journal of Veterinary Clinics
    • /
    • v.39 no.2
    • /
    • pp.87-92
    • /
    • 2022
  • A 14-year-old castrated male Persian cat presented with a 2-week history of respiratory difficulty. On physical examination, the patient showed intermittent open-mouth breathing and thoracic auscultation revealed wheezing. Thoracic radiographs revealed a narrowed upper airway and pulmonary infiltration. Computed tomography detected a mass occluding the lumen of the trachea at the level of the entrance to the thorax, a mass causing right main bronchus stenosis, and a nodule on the right caudal lung lobe. Bronchoalveolar lavage cytology tentatively diagnosed a carcinoma. Tracheal mass resection was performed through tracheostomy. Histopathology confirmed the presence of tracheobronchial carcinoma. The survival time after diagnosis was 10 months, during which time the cat underwent tracheostomy, debulking by endotracheal tube, and tracheal stent placement procedures in combination with toceranib phosphate adjuvant chemotherapy.

Cytotoxic Effects on HL-60 Cells of Myosin Light Chain Kinase Inhibitor ML-7 Alone and in Combination with Flavonoids

  • Lee, Joong-Won;Kim, Yang-Jee;Choi, Young-Joo;Woo, Hae-Dong;Kim, Gye-Eun;Ha, Tae-Kyung;Lee, Young-Hyun;Chung, Hai-Won
    • Toxicological Research
    • /
    • v.25 no.4
    • /
    • pp.181-188
    • /
    • 2009
  • Uncontrolled cell growth and increased cell proliferation are major features of cancer that are dependent on the stable structure and dynamics of the cytoskeleton. Since stable cytoskeleton structure and dynamics are partly regulated by myosin light chain kinase (MLCK), many current studies focused on MLCK inhibition as a chemotherapeutic target. As a potent and selective MLCK inhibitor, ML-7 [1-(5-iodonaphthalene-1-sulfonyl)-1 H-hexahydro-1,4-diazapine hydrochloride] is a promising candidate for an anticancer agent, which would induce apoptosis as well as prevents invasion and metastasis in certain types of cancer cells. This study assessed cytotoxic effects of ML-7 against HL-60 cells and therapeutic efficacy of ML-7 as a potential antileukemia agent. Trypan-blue exclusion assays showed dose- and time- dependent decreases in ML-7 treated HL-60 cells (p<0.05). Comet assays revealed a significant increase in DNA damage in HL-60 cells after treatment with $40{\mu}M$ ML-7 for 2h. Sub-G1 fractions, analyzed by flow cytometry increased in a dose-dependent manner, suggesting that ML-7 can induce apoptotic cell death in HL-60 cells. ML-7 was selectively cytotoxic towards HL-60 cells; not affecting normal human lymphocytes. That selective effect makes it a promising potential anti-leukemia agent. In addition, anticancer efficacy of ML-7 in combination with flavonoids (genistein or quercetin) or anticancer drugs (cisplatin or Ara-C) against HL-60 cells was assessed. Combination of ML-7 with flavonoids increased the anti-cancer effect of ML-7 to a greater extent than combination with the anticancer drugs. This implies that ML-7 in combination with flavonoids could increase the efficacy of anticancer treatment, while avoiding side effects cansed by conventional anticancer drug-containing combination chemotherapy.